A Great stock from Pharmaceuticals

Suven Pharma is in the business of contract development & manufacturing organization ( CDMO ), catering to the needs of the global Pharma Industry
SPL engages in NCE molecule development and supply of intermediates. This is a high-value-add, high-margin business. SPL supplies intermediates for four molecules addressing rheumatoid arthritis, diabetes, depression, and women’s health. This segment makes up 78% of revenues. The company has a strong order book with new clients being consistently added. Most clients are the Big Pharma companies in Europe and the US. The company is looking to shift from Intermediate to API manufacturing and is in discussion with clients regarding this. The company has stated that it has the facilities for API manufacturing
After the initial bullishness it has been range-bound now the Darvas box has broken with volume , can be considered for long

Trade only on your DUE DILIGENCE

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.